252 related articles for article (PubMed ID: 22583145)
1. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
van den Hoogen MW; Hoitsma AJ; Hilbrands LB
Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
5. [The role of polyclonal anti-T-lymphocyte antibodies (ATG) in the kidney transplantation].
Nikolovski M; Kotsev Iu; Dimitrov S; Nikolova M; Panchev P
Khirurgiia (Sofiia); 2004; 60(4-5):42-5. PubMed ID: 16042064
[TBL] [Abstract][Full Text] [Related]
6. Is there any role for antithymocyte induction in renal transplantation?
Neidlinger NA; Sollinger HW
Transplant Proc; 2010 Jun; 42(5):1402-7. PubMed ID: 20620444
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
[TBL] [Abstract][Full Text] [Related]
8. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
Burk ML; Matuszewski KA
Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients.
Bamoulid J; Courivaud C; Crepin T; Carron C; Gaiffe E; Roubiou C; Laheurte C; Moulin B; Frimat L; Rieu P; Mousson C; Durrbach A; Heng AE; Rebibou JM; Saas P; Ducloux D
Kidney Int; 2016 May; 89(5):1136-1143. PubMed ID: 27083287
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
13. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
14. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
Zheng J; Song W
Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
18. The utility of cytodiagnostic urinalysis as a tool to diagnose kidney allograft dysfunction in the era lymphocyte-depleting induction therapy.
Mehta T; Sanaei-Ardekani M; Farooqi A; Khan S; Shammas A; Boonyapredee M; Allston C; Wu J; Nsouli H; Pehlivanova M
Transplant Proc; 2011 Dec; 43(10):3679-85. PubMed ID: 22172825
[TBL] [Abstract][Full Text] [Related]
19. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
20. No synergy between ATG induction and costimulation blockade induced kidney allograft survival in rhesus monkeys.
Haanstra KG; Sick EA; Ringers J; Wubben JA; Kuhn EM; 't Hart BA; Boon L; Jonker M
Transplantation; 2006 Nov; 82(9):1194-201. PubMed ID: 17102771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
